TWENTIETH CONGRESS OF THE 
REPUBUC OF THE PHILIPPINES 
First Regular Session
)
SENATE
S. No. 15
25 JUL-2 P4:27
Introduced by Senator Robinhood Padilla
AN ACT
PROVIDING FOR THE MEDICALIZATION OF CANNABIS, EXPANDING 
ACCESS TO MEDICAL CANNABIS AS A MEANS OF MEDICAL TREATMENT, 
EXPANDING RESEARCH INTO ITS MEDICINAL PROPERTIES, 
ENUMERATING PROHIBITED ACTS AND PRESCRIBING PENALTIES 
THERETO
EXPLANATORY NOTE
The 1987 Constitution guarantees every Filipino's rights to life, liberty, and the 
pursuit of well-being. These include the right to health and the right to make informed 
decisions about one's own medical treatment — a cornerstone of patient autonomy. 
This proposed measure seeks to uphold that right through the medicalization of 
cannabis in the country.
In 2020, the United Nations Commission on Narcotic Drugs, based on the 
recommendation of the World Health Organization, reclassified cannabis from 
Schedule IV to Schedule I on the ground of its medical use and potential abuse. 
Scientific evidence that medical cannabis possesses therapeutic benefits, particularly 
for individuals suffering from debilitating medical conditions such as epilepsy, chronic 
pain, multiple sclerosis, cancer, and other terminal or life-altering illnesses is 
continuously growing in many countries across the globe.
This bili is anchored on science and evidence contained in many researches and 
medical journals that states that medical cannabis can serve as a complementary or


alternative treatment to alleviate the suffering of patients who continue to endure 
pain, seizures, or loss of function, despite undergoing conventional treatments.
The bill also proposes the creation of the Philippine Medical Cannabis Authority 
(PMCA) under the Department of Heaith, which shail serve as the key agency that wiil 
regulate every aspect of the medical cannabis ecosystem—from cuitivation, 
manufacturing, labeliing to prescription, dispensation, and monitoring.
Safeguards through reguiatory measures are iikewise embedded throughout 
the biil to ensure that misuse and diversion are prevented. These safety nets inciude 
the foiiowing: a) Issuance of prescriptions only by trained, licensed physicians with an 
S2 license; b) Establishment of a Prescription Monitoring System and a Cannabis Piant 
Monitoring System; c) Limitation of use oniy to specific, serious and debilitating 
medical conditions; d) QR-coded patient registry cards and electronic verification 
protocols; and e) Strict licensing, location zoning, and security requirements for 
industry players.
The bill also penalizes any individual, whether a patient, doctor or industry 
player that commits any of the prohibited acts and violates any provision of the 
measure.
During the 19th Congress, a version of this bill was approved on third and final 
reading at the House of Representatives while this Senate version had already reached 
the Plenary until the period of interpellations. This feat, which was the farthest that a 
medical cannabis had reached in Congress demonstrates the strong and growing 
consensus among legislators for compassionate and science-based healthcare reform.
Contrary to the fears of many, this legislation is not, in any way, paving the 
road toward the recreational use of cannabis. It is a clearing the way to a responsible, 
health-centered response to human suffering, guided by science, ethical principles, 
and stringent safeguards. Through this measure, we are not only expanding treatment 
options for our countrymen — we are reaffirming the dignity of every Filipino patient 
and their right to choose a better quality of life.


In view of the foregoing, the immediate passage of this bill is earnestly sought.
OBINHOOD PADILLA
Senator


TWENTIETH CONGRESS OF THE 
REPUBUC OF THE PHILIPPINES 
First Regular Session
SENATE
S. No. 15
25 JUL-2 P4:27
Introduced by Senator Robinhood Padilla
AN ACT
PROVIDING FOR THE MEDICALIZATION OF CANNABIS, EXPANDING 
ACCESS TO MEDICAL CANNABIS AS A MEANS OF MEDICAL TREATMENT, 
EXPANDING RESEARCH INTO ITS MEDICINAL PROPERTIES, 
ENUMERATING PROHIBITED ACTS AND PRESCRIBING PENALTIES 
THERETO
Be it enacted by the Senate and House of Representatives of the Philippines in 
Congress assembled:
1 
Section 1. Short Title. -This Act shall be known as the " Cannabis Medicalization
2 
Act of the Philippines."
3 
Sec. 2. Declaration of Policy. -It is the policy of the State to adopt an integrated
4 
and comprehensive approach to health development which shall endeavor to make
5 
essential goods, health, and other social services available to all the people at
6 
affordable cost. The State shall protect and promote the right to health of the people
7 
and instill health consciousness among them. Pursuant thereto, the State shall legalize
8 
and regulate the medical use of cannabis which has been confirmed to have beneficial
9 
and therapeutic uses for known debilitating medical conditions.
10 
Sec. 3. Definition of Terms. - As used in this Act.'
11 
a. C^/7/75Z?/5includes every species and variety of the genus cannabis, whether
12 
dried or fresh and flowering or fruiting tops, or any part or portion of the
13 
plant and seeds thereof, and all its geographic varieties, whether as a
14 
reefer, resin, extract, tincture or in any form whatsoever;


1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26 
27
b. 
Closed Locked and Controlled Facility refers to a closet, room or other 
comparable, stationary, and fully enclosed area equipped with secured 
locks, or other functioning security devices that permit access only to 
authorized personnel of the medical cannabis industry players' cultivation, 
extraction, processing, manufacturing and production sites and dispensary;
c. 
Debilitating Medical Condition refers to a condition that is severe, 
persistent, and seriously affecting the patient's strength and ability to 
function and carry on most of daily living activities, as identified and 
included in the Good Clinical Practice to be formulated and developed by 
the Philippine Medical Cannabis Authority (PMCA) established under this 
Act;
d. 
Medical Cannabis refers to cannabis based medicinal products (CBMP) in 
their pharmaceutical formulation which shall contain cannabidiol (CBD) with 
no more than 0.3 percent (0.3%) tetrahydrocannabinol (THC). THC shall 
only be allowed as a component of CBD.
e. 
Medical use refers to the use of medical cannabis as a complementary 
treatment to alleviate a qualified patient's debilitating medical condition or 
symptoms, and shall include its acquisition, possession, transportation, 
delivery, dispensation, administration, cultivation, or manufacturing, 
research and development for medical purposes;
f. 
S2 License refers to a license issued by the PDEA to a Professional 
Regulatory Commission (PRC)-registered physician; and
g. 
Written Prescription refers to a document dated and signed by a PRC- 
registered physician possessing an S2 License, containing the debilitating 
medical condition of the qualified patient under Section 8 of this Act, the 
recommended dosage of medical cannabis, and treatment plan for palliative 
care.
28 
Sec. 4. Medicalization of Cannabis. - The use of cannabis for medical purposes,
29 
as herein provided under this Act, is hereby permitted, in the formulation provided


1 
under Sec. 3(d) hereof, to treat or alleviate a qualified patient's debilitating medical
2 
condition or symptoms. The medicalization of cannabis includes its acquisition,
3 
possession, transportation, delivery, dispensing, administration, cultivation, or
4 
manufacturing by private individuals or entities only for medical and research
5 
purposes.
6 
Sec. 5. Philippine Medical Cannabis Authority. - There shall be created a
7 
Philippine Medical Cannabis Authority, herein referred to as "PMCA" under the
8 
Department of Health (DOH), which shall be the principal regulatory agency in the
9 
access and use of medical cannabis and in the implementation of this Act. It shall be
10 
headed by a Director to be designated by the President of the Republic of the
11 
Philippines upon recommendation of the Secretary of Health.
12 
The DOH shall organize the Authority, including its staffing pattern, and shall
13 
ensure its knowledge, competence, and experience with the use of cannabis and
14 
regulation of dangerous drugs for medical purposes. Necessary staffing requirements
15 
may be requested from the Department of Budget and Management.
16 
The PMCA shall be assisted by an inter-agency Medical Cannabis Advisory
17 
Committee.
18 
Sec. 6. Powers and Functions of the Philippine Medical Cannabis Authority. -
19 
The PMCA shall have the following powers and functions:
20
21
22
23
24
25
26
27
28
a. To formulate and adopt a Comprehensive Cannabis Medicaiization Pian;
b. To formulate, adopt and implement rules, regulations, and guidelines 
related to medical cannabis plants, its products and by-products, including 
but not limited to, propagation, cultivation, planting, harvesting, 
processing, manufacturing, packaging, labeling, distribution, dispensing, 
and patient licenses or prescription;
c. 
To establish and maintain an information system especially to track 
cannabis growth from seed to sale for monitoring and regulation purposes: 
Provided, That the PMCA shall monitor or regulate the cultivation.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26
manufacture, storage, distribution, prescription, dispensation and sale of 
medical cannabis by licensed dispensaries;
d. To formulate, adopt, publish and implement Standard Operating 
Procedures for every stage of producing medical cannabis, such as, but not 
limited, to the following:
i. 
Good Clinical Practice (GCP);
ii. 
Good Agriculture Practice (GAP);
Hi. 
Good Manufacturing Practice (GMP);
iv. 
Good Distribution Practice (GDP);
V. 
Good Waste Disposal Practice (GWDP); and
vi. 
Good Security Practice (GSP).
e. To issue licenses to duly registered entities or persons, private or 
government, that shall engage as medical cannabis industry players 
through cultivation, manufacturing, production, dispensing, research and 
development, and importation and sale of medical cannabis;
f. 
To regularly and continuously conduct research and development on the 
medical cannabis industry and apply the same to further develop the 
industry in the country;
g. To conduct or sponsor or arrange or permit training and educational 
programs on specific aspects of the medical cannabis industry: Provided, 
That the said training and educational programs shall be a prerequisite to 
permitting licensed physicians to prescribe and other medical practitioners 
to dispense medical cannabis products or by-products;
h. To establish a Prescription Monitoring System and maintain an electronic 
database of registered medical cannabis patients, their physicians, and 
other qualified entities for monitoring and regulation purposes;


1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
26 
27
i. 
To hold seminars, workshops, conferences and information dissemination 
campaigns on the medical cannabis industry, its products, and by-products, 
particularly on the therapeutic and medical effects of cannabis as 
authorized in this Act and the risk associated with the use of cannabis for 
recreational activities;
j. 
To make recommendations to the Commission on Higher Education to 
include medical cannabis as a subject or course in the curriculum of 
universities and colleges for academic degrees in agriculture, medicine, and 
applied science and technology;
k. To make recommendations to PRC to develop and implement a Continuing 
Professional Development Program on Medical Cannabis for physicians, 
pharmacists, and other allied medical and health care professionals;
l. 
To hire or contract consultants, local or foreign, individuals or entities, for 
technical capacity building;
m. To import for resale in the Philippines for authorized users medical cannabis 
products from foreign manufacturers or companies; Provided, That the said 
medical cannabis products comply with the safety and quality standards 
prescribed by PMCA, in consultation with the Advisory Committee as 
provided for in this Act: Provided further, That the testing of any medical 
cannabis product to determine its potency, consistency, safety and 
effectivity, as well as compliance with packaging and labeling safety 
requirements shall remain with the Food and Drug Administration (FDA);
n. To regulate prices of medical cannabis products in the country;
0. To accept grants and technical assistance in support of medical cannabis 
research and development; and
p. To perform other functions as may be deemed necessary to aid the 
implementation of this Act.


1 
Sec. 7. Advisory Committee on Medicai Use of Cannabis. - There is hereby
2 
constituted an advisory committee on the medical use of cannabis, hereinafter referred
3 
to as the Medical Cannabis Advisory Committee (MCAC), which shall assist and provide
4 
directions in the formulation, implementation and assessment of the policies,
5 
guidelines, and regulations under this Act.
6 
The Secretary of Health shall serve as the ex-officio chairperson of the MCAC.
7 
The Chairman of the Dangerous Drugs Board (DDB), the Directors-General of the FDA
8 
and the PDEA, the Secretary of Science and Technology and the Secretary of
9 
Agriculture or their respective representatives shall be permanent members of the
10 
Medical Cannabis Advisory Committee.
11 
The Secretary shall appoint the seven regular members of the MCAC who shall
12 
serve for a term of three (3) years. It shall be comprised of three (3) PRC-registered
13 
physicians, two (2) experts in the regulation of controlled substances for medical use,
14 
and two (2) representatives from nationally recognized organizations of patients with
15 
debilitating medical conditions: Provided, That the seven regular members must be
16 
citizens and residents of the Philippines, of good moral character, of recognized probity
17 
and independence, and must distinguish themselves professionally in public, civic or
18 
academic service and must have been in the practice of their professions for at least
19 
ten (10) years: Provided, further. That the regular members shall nominate a Vice-
20 
Chairperson from among themselves, and shall receive an honoraria in accordance
21 
with existing laws, rules and regulations.
22 
The MCAC shall meet once a month or as often as necessary at the discretion
23 
of the Chairperson.
24 
Sec. 8. Quaiified Patient - The qualified patient is a person who has been
25 
diagnosed by a certifying physician as having a debilitating medical condition as
26 
defined in Section 3 (c) and may receive therapeutic or palliative benefits from the
27 
use of medical cannabis. Qualified patients shall be registered with the PMCA and
28 
assigned a unique alphanumeric identification number and shall be issued a registry
29 
card with a quick response (QR) code for verification.


1 
If the qualified patient is a minor or is incapable or incapacitated to fully give
2 
his consent, regardless of age, the certifying physician shall explain to the patient and
3 
to the custodial parent or legal guardian the potential risks and benefits of using
4 
medical cannabis. The custodial parent or legal guardian shall signify, in writing, their
5 
consent to allow the qualified patient's medical use of cannabis.
6 
Sec. 9. Issuance of Written Prescription, Requisites. - A written prescription
7 
allowing the use of medical cannabis shall be recognized and accepted if issued by a
8 
physician who:
9 
a. 
Is duly licensed by the PRC and in good standing;
10 
b. 
Has no previous or existing criminal or administrative case/s; and
11 
c. 
Is a holder of an S2 license issued by PDEA and has undergone
12 
appropriate medical cannabis training from PMCA.
13 
The certifying physician shall not issue a written prescription for his or her own
14 
use, or the use of his or her immediate family or relatives within the second civil
15 
degree of consanguinity or affinity.
16 
The certifying physician shall maintain a record of all his issued written
17 
prescriptions. He or she shall be responsible for maintaining a record of every qualified
18 
patient prescribed the use of medical cannabis, specifically describing the quantity
19 
administered/used, therapeutic/desired effect, and any adverse reaction, at the end
20 
of each year.
21 
Sec. 10. Vaiidity of Prescription. - The written prescription issued by all
22 
certifying physicians shall include a validity period which shall in no case exceed one
23 
(1) year from the date of issuance.
24 
Sec. 11. Grounds for Revocation of Prescription. - Any prescription issued by a
25 
certifying physician may be revoked based on the following reasons:
26
27
a. 
Misuse or diversion of the written prescription;
b. Failure to abide by the prescribed dosage and form;


1 
c. The patient no longer suffers from a debilitating medical condition;
2 
d. The patient has not received a therapeutic or palliative benefit from the use
3 
of medical cannabis; and
4 
e. When the qualified patient has died.
5 
Sec. 12. Standardized Written Prescription. - The PMCA shall develop and
6 
require the use of a standardized format for all written prescriptions and the same
7 
shall be made available to all certifying physicians.
8 
The standardized format shall include the following details: (a) name, date of
9 
birth, and address of the qualified patient; (b) a statement that the qualified patient
10 
has debilitating medical condition as provided in Section 3 (c) and that the qualified
11 
patient is under the certifying physician's care for the debilitating medical condition;
12 
(c) recommended form and dosage of medical cannabis; (d) issue and expiry date of
13 
the prescription; and (e) name, address, telephone number, handwritten signature.
14 
Sec. 13. Administration of Medicai Cannabis. - Medical cannabis may be
15 
administered through the following: (a) oral; (b) sublingual; (c) inhalation inhalers;
16 
(d) topical; and (e) suppositories.
17 
Sec. 14. Medicai Cannabis Industry Piayers. - Only duly registered entities or
18 
persons shall be allowed to engage as medical cannabis industry players to conduct
19 
any of the following acts in relation to medical cannabis: (a) cultivation; (b)
20 
manufacturing; (c) production; (d) dispensing; (e) research and development; (f)
21 
importation; and (g) dispensing and sale: Provided, That all industry players shall
22 
apply and be issued appropriate licenses by the PMCA and other national government
23 
agencies concerned prior to engagement in any business operations as regards
24 
medical cannabis: Provided further. That industry players shall be strictly regulated
25 
and shall, at all times, comply with the provisions of this Act and the rules, regulations,
26 
guidelines and standard operating procedures to be formulated for its implementation.
27 
Sec. 15. Cuitivation, Production and Manufacturing of Cannabis. -The specific
28 
areas allowable for the cultivation of cannabis shall be identified by the PMCA:
29 
Provided, That cultivation shall only be permitted in a closed locked and controlled
8


1 
facility and that cultivation shall not be located within one (1) kilometer of the property
2 
line of a pre-existing public or private school, college or university, daycare center,
3 
child care facility or an area zoned for residential use: Provided, further, That colleges
4 
or universities conducting research and development on medical cannabis are
5 
exempted from the one (1) kilometer radius requirement.
6 
The PMCA shall issue appropriate licenses and permits for the cultivation,
7 
production, and distribution of medical cannabis subject to DDB guidelines. It shall
8 
also adopt measures that will ensure the prevention of misuse and illicit traffic of the
9 
cannabis plant, such as the establishment of a cannabis plant monitoring system.
10 
The PMCA is hereby authorized to engage consultancy services of foreign
11 
cannabis experts for the initial cultivation and production of medical cannabis.
12 
The PMCA shall facilitate the initial importation of seeds required for the
13 
cultivation and production of medical cannabis: Provided, That the imported seeds are
14 
used solely for the initial cultivation of locally grown cannabis: Provided further. That
15 
importation of seeds shall be allowed only in the initial stage of the implementation of
16 
this Act or a period of not more than five (5) years or until the industry players are
17 
fully capacitated to independently cultivate locally-grown cannabis.
18 
Sec. 16. Medicai Cannabis Products. -Medical cannabis products shall be in the
19 
form of edibles, pills, oil, tincture, flower, topicals, and inhalers. Importation of the
20 
same products from countries with stringent regulatory agencies or countries with
21 
established medical cannabis regimes or countries already using the same medical
22 
cannabis products in the last five years, shall be allowed under this Act. Importation
23 
of medical cannabis products from countries not using their own products shall be
24 
prohibited.
25 
Sec. 17. Medicai Cannabis Product Labe! and Packaging. - All medical cannabis
26 
products shall be properly and adequately labeled like that of any pharmaceutical
27 
products. The label shall contain the following information, among others:
28 
a. CBD and THC content and ratio;
29
b. Batch and Series number;


1 
c. Date of production and expiration;
2 
d. Clinical Indications and Contraindications;
3 
e. Dosage and Administration Instruction;
4 
f. Storage Instruction; and
5 
g. Other relevant information as may deemed necessary by the PMCA.
6 
Sec. 18. Dispensing Medical Cannabis. - Prior to dispensing medical cannabis,
7 
the authorized dispensaries must require the presentation of the registry ID card, scan
8 
the QR code, examine the details, and update the data contained therein after the
9 
sale. The QR code shall contain details such as the name of the certifying physician,
10 
the assigned unique alphanumeric identification number of the patient, the diagnosed
11 
medical condition of the qualified patient, the prescribed dosage, medical cannabis
12 
product and formulation, the duration of use, and the complete transaction history of
13 
the qualified patient.
14 
Sec. 19. Authorized Transport Vehicies. - Only authorized transport vehicles
15 
shall be authorized to carry and transport medical cannabis plants and products.
16 
Sec. 20. Eiectronic Verification. - The PMCA shall establish a Prescription
17 
Monitoring System which shall be made accessible to the PDEA Compliance Service
18 
and authorized dispensaries where they may electronically verify and determine the
19 
validity of the registry ID card and information on whether the cardholder is a
20 
registered qualified patient.
21 
Sec. 21. Cannabis Plant Monitoring System. -The cultivation facilities shall
22 
establish and maintain a Cannabis Plant Monitoring System for testing and data
23 
collection. It shall be available for inspection of regulatory agencies for purposes of
24 
documenting each cannabis plant and for monitoring plant development throughout
25 
the life cycle from seed planting to final packaging.
26 
Sec. 22. Authority of the PMCA to Enter Premises. -To ensure compliance with
27 
the provisions of this Act, the PMCA may, at all times, enter every building, room,
28 
enclosure, or premises occupied or used for the cultivation, production, preparation.
10


1
2
3
4
5
6
7
8 
9
10
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
manufacture for sale, storage, and sale of medical cannabis, and to inspect the 
premises and all equipment, apparatuses, fixtures, furniture, and machinery used for 
the preparation thereof.
Sec. 23. Testing of Medical Cannabis. -The PMCA shall test all medical cannabis 
products prior to their distribution, dispensation, and sale to determine their potency, 
consistency, safe and effective use. It shall ensure that all medical cannabis products 
are medical grade and safe for use.
It shall ensure that all medical cannabis products are individually wrapped at 
the original point of preparation and conform to existing packaging and labeling 
requirements of the PMCA and FDA.
11 
Sec. 24. Exemption from Civil and Criminal Liability. - Subject to Section 25 of
12 
this Act, the following shall be exempt from civil and criminal liability:
a. The certifying physician, as defined in Section 9 of this Act, for issuing 
written prescriptions stating that in the physician's professional opinion, 
a patient is qualified to receive therapeutic or palliative benefit from the 
medical use of cannabis to treat or alleviate the patient's debilitating 
medical condition or symptoms;
b. A qualified patient for using medical cannabis in the prescribed dosage 
and form for treatment of his debilitating medical condition as 
determined by a certifying physician;
c. An authorized representative for assisting a registered qualified patient 
for possessing not more than the exact prescribed dosage of cannabis 
needed by the qualifying patient;
d. The licensed medical cannabis industry players and their personnel 
authorized to dispense, cultivate, manufacture, or produce medical 
cannabis as provided under this Act; and
e. Personnel of national government agencies tasked with testing medical 
cannabis and cannabis products, and other similar undertakings which
11


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
would require handling, transporting or otherwise possessing cannabis 
and cannabis products: Provided, That the said personnel of national 
government agencies are authorized by the PMCA to perform such 
undertakings: Provided further, That the said personnel are performing 
such undertakings while on duty inside an authorized or licensed 
cultivation, production, testing and dispensing facility.
Sec. 25. Prohibited Acts. - It shall be prohibited for:
a. A qualified patient to:
i. 
Use cannabis for purposes other than for treatment of a 
debilitating medical condition and outside of the designated 
treatment facilities;
ii. 
Use of cannabis with other illegal intoxicating or dangerous 
substances; and
iii. 
Sell or give away medical cannabis.
b. Any physician to:
i. 
Prescribe medical cannabis without an S2 license;
ii. 
Prescribe medical cannabis to any person who is not a qualified 
patient under this Act;
iii. 
Prescribe the use of medical cannabis for purposes other than for 
treatment of a debilitating medical condition;
iv. 
Prescribe medical cannabis in quantity more than the needed 
dosage;
V. Fail or refuse to maintain the record of all his or her patients and 
prescriptions issued referred to in Section 9 of this Act; and
12


1
2
3
4
5
6
7
8
vi. Issue a written prescription for his or her own use, or the use of 
his or her immediate family or relatives within the second civil 
degree of consanguinity or affinity.
c. A Medical Cannabis Industry Player to:
i. 
Operate as a medical cannabis industry player without a license;
ii. 
Acquire, possess, deliver, transfer, transport, supply, or dispense 
medical cannabis to any person except to registered qualified 
patients or through their authorized representatives;
iii. 
Cultivate, manufacture, and store cannabis/medical cannabis in
10
violation of any of the provisions of this Act;
11
iv.
Acquire usable cannabis or mature cannabis plants from illegal
12
sources;
13
V.
Refer patients to an unqualified physician;
14
vi.
Dispense without presentation of the certifying physician's written
15
prescription and valid registry ID card of the qualified patient or
16
its authorized representative;
17
vii.
Dispense more than the required dosage for a patient; and
18
viii.
Fail to scan the QR Code of any qualified patient and update the
19
Prescription Monitoring System prior to dispensing cannabis.
20
d. Any person or entity to:
21
i.
Advertise the sale of medical cannabis in any manner, including
22
printed materials, on radio or television, social media, internet or
23
by paid-in-person solicitation of customers, and electronic games:
24
Provided, That this shall not be construed to prohibit medical
25
cannabis industry players from posting appropriate signages in
26
their place of business or operation, and from being included in
27
business directories, or sponsoring or organizing health, charity
13


1 
or advocacy events, subject to the guidelines to be issued by the
2 
PMCA;
3 
ii. Violate the confidentiality of information under R.A. 10173,
4 
otherwise known as the "Data Privacy Act of 2012')
5 
iii. 
Purchase of medical cannabis when not authorized to do so;
6 
iv. 
Falsifies an identification card issued by the DOH or an S2 license
7 
or possesses a falsified identification card and either attempts to
8 
use the card to obtain medical cannabis or obtains medical
9 
cannabis. Any person using or possessing a falsified identification
10 
card shall be presumed the author thereof; and
11 
V. Discriminates any qualified patient from any services in public or
12 
private establishment; employment in any public or private
13 
institution; or admission to any academic institution: Provided,
14 
That the qualified patient shall not partake in medical cannabis
15 
within the premises of the place of employment or the academic
16 
institution.
17 
Sec. 26. Penaities. - Violation of any provisions of this Act shall be subject to
18 
the penalties provided for under Republic Act No. 9165, as amended, or the
19 
"Comprehensive Dangerous Drugs Act of 2002".
20 
Sec. 27. Research and Deveiopment - The PMCA shall, within one hundred
21 
twenty (120) days from the approval of this Act, use existing research made by
22 
reputable international organizations, as well as research made or published by its
23 
counterpart in countries wherein medical cannabis is administered.
24 
Sec. 28. Medical Cannabis Research and Development Fund. - A portion of the
25 
proceeds from licensing and registration of medical cannabis industry players shall be
26 
earmarked for the medical cannabis industry research, protection and development.
27 
Sec. 29. Training of Medical Cannabis Physicians, Pharmacists, and Other Allied
28 
Medical and Health Care Professionals. - The PMCA shall develop an appropriate
14


1 
training program for physicians, pharmacists, and other allied medical and health care
2 
professionals on the following topics: the pharmacology of cannabis;
3 
contraindications; side effects; adverse reactions; overdose prevention; drug
4 
interactions; dosing; routes of administration; risks and benefits; warnings and
5 
precautions; abuse and dependence, and other related topics. Completion of the
6 
program shall be a precondition for the physician, pharmacists, and other allied
7 
medical and health care professionals, as may be licensed, to prescribe, dispense and
8 
administer medical cannabis to qualified patients.
9 
The PMCA shall coordinate with the Commission on Higher Education to
10 
integrate the aforementioned topics on medical cannabis into the medical curriculum
11 
of all medical schools, and academic curriculum for agriculture and applied science
12 
and technology in all colleges and universities.
13 
The PMCA shall likewise coordinate with the PRC for the development and
14 
implementation of a Continuing Professional Development program on medical
15 
cannabis for certified physicians.
16 
Sec. 30. Annual Reports. -The PMCA shall submit an annual report to the DOH
17 
and to both Houses of Congress, which shall include the following information:
18
19
20 
21 
22
23
24
25
26
a. 
Number of applications and renewals filed for registry identification cards;
b. Number of registered qualified patients at the time of report;
c. 
Nature of debilitating medical conditions of the qualified patients;
d. Number of physicians authorized to issue prescriptions;
e. 
Number of registry identification cards revoked for misconduct;
f. 
Number of medical cannabis industry players;
g. Assessment of the use of medical cannabis, research, and treatment of 
patients with a debilitating medical condition; and
h. Other pertinent information.
15


1 
Sec. 31. Joint Congressional Oversight Committee. -There is hereby created a
2 
Joint Congressionai Oversight Committee to conduct a reguiar review of the
3 
impiementation of this Act.
4 
The Joint Congressionai Oversight Committee shaii be composed of five (5)
5 
Members from the Senate and five (5) Members from the House of Representatives
6 
to be appointed by the Senate President and the Speaker of the House of
7 
Representatives, respectiveiy. The Joint Congressional Oversight Committee shaii be
8 
jointly chaired by the Chairpersons of the Senate Committee on Health and
9 
Demography and the House of Representatives Committee on Health.
10 
Sec. 32. Implementing Rules and Regulations. - Within ninety (90) days from
11 
the effectivity of this Act, the PMCA, in consuitation with the appropriate government
12 
agencies, shaii promuigate ruies and reguiations necessary for the effective
13 
implementation of this Act.
14 
Sec. 33. Appropriations. - The amount necessary to carry out the
15 
implementation of this Act shaii be charged against the current year's appropriations
16 
of the DOH. Thereafter, such sums as may be necessary for the continued
17 
implementation of this Act shaii be inciuded in the annual General Appropriations Act.
18 
Sec. 34. Separability Clause. - If any provision or part of this Act is declared
19 
invalid or unconstitutionai, the remaining parts or provisions not affected shaii remain
20 
in fuil force and effect.
21 
Sec. 35. Repealing Clause. - For purposes of this Act, pertinent provisions of
22 
Republic Act No. 9165, as amended, otherwise known as the "Comprehensive
23 
Dangerous Drugs Act of 2002," as amended, and Repubiic Act No. 9711 or the "Food
24 
and Drug Administration Act of 2019", and ali other laws, decrees, orders, rules and
25 
regulations, or parts thereof, inconsistent with any provision of this Act, are hereby
26 
repeaied or modified accordingly.
27 
Sec. 36. Effectivity. -This Act shaii take effect after fifteen (15) days from its
28 
publication in the Official Gazette or in a newspaper of general circulation.
Approved,
16